表紙
市場調查報告書

慢性阻塞性肺病(COPD)治療藥的全球市場:2016∼2020年

Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 364923
出版日期 內容資訊 英文 118 Pages
訂單完成後即時交付
價格
Back to Top
慢性阻塞性肺病(COPD)治療藥的全球市場:2016∼2020年 Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023
出版日期: 2019年01月18日內容資訊: 英文 118 Pages
簡介

慢性阻塞性肺病是慢性的支氣管炎和肺氣腫的症狀組合,慢性支氣管炎導致細微支氣管的發炎,肺氣腫是肺泡牆遭破壞,造成呼吸困難。全球慢性阻塞性肺病治療藥市場,預計2016∼2020年以4.85%的年複合成長率擴大。

本報告提供全球慢性阻塞性肺病(COPD)治療藥市場相關調查,市場成長預測,各地區趨勢,市場趨勢與課題,主要供應商的競爭趨勢等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 開發平台分析

第6章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 慢性阻塞性肺病治療藥的購買標準

第8章 慢性阻塞性肺病治療藥的全球市場:各類藥物市場分類

  • 聯合治療
  • 支氣管擴張劑
  • 類固醇
  • 白三烯拮抗劑
  • PDE-4抑制劑
  • 其他

第9章 慢性阻塞性肺病治療藥的全球市場:各給藥途徑分類

  • 吸入
  • 口服

第10章 慢性阻塞性肺病治療藥的藥物輸送設備市場

  • 市場概要
  • 各產品類型市場分類

第11章 慢性阻塞性肺病治療藥的全球市場:各地區分類

  • 各地區市場
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區
  • 中國

第12章 慢性阻塞性肺病治療藥的全球市場:促進要素

  • 抽煙
  • LABA/LAMA的聯合治療的攝取
  • 一時性治療藥認證造成的堅固開發平台

第13章 促進要素的影響

第14章 慢性阻塞性肺病治療藥的全球市場:課題

  • 開發平台分子的技術創新不足
  • 對控制器治療藥的使用的懈怠
  • 低的診斷率

第15章 促進要素與課題的影響

第16章 慢性阻塞性肺病治療藥的全球市場:趨勢

第17章 供應商環境

  • 競爭模式
  • 主要消息

第18章 主要供應商分析

  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Novartis
  • Teva Pharmaceuticals
  • 其他值得注意的供應商

第19章 附錄

第20章 關於Technavio

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR30709

About this market

COPD is a chronic non-communicable, lifestyle-related disease, which progresses continuously in the absence of medical intervention. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. exposure to second-hand or passive smoking. smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status. and dietary factors, which lead directly or indirectly to COPD. Apart from lifestyle factors, there are factors such as old age and presence of rare genetic disorders. which contribute to the rising prevalence of COPD. Technavio's analysts have predicted that the chronic obstructive pulmonary disease (COPD) drugs market will register a CAGR of almost 4% by 2023.

Market Overview

Strong pipeline and new drug approvals

The pipeline for the treatment of COPD includes several drug combinations, which can provide a wide range of therapeutic benefits. These drug combinations are presently in the late stages of development, with some expected to be launched in the market during the forecast period. These molecules combine the properties of drugs from different classes and have diversified therapeutic mechanisms of action and hence are expected to change the course of COPD treatment.

Low diagnosis rates for COPD

There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.

For the detailed list of factors that will drive and challenge the growth of the chronic obstructive pulmonary disease (COPD) drugs market during the 2019-2023, view our report.

Competitive Landscape

The chronic obstructive pulmonary disease (COPD) drugs market appears to be moderately concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Chronic bronchitis
  • Emphysema

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global respiratory disorder drugs market
  • Exhibit 03: Segments of global respiratory disorder drugs market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Pipeline molecules for COPD
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Sales of monotherapy drugs 2015-2017 ($ millions)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Decision framework
  • Exhibit 41: Mechanism of action of budesonide/ glycopyrronium/formoterol triple combination
  • Exhibit 42: New drug approvals for COPD
  • Exhibit 43: US FDA-approved fixed-dose combination LABAs and LAMAs
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Examples of advanced nebulizers
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: AstraZeneca - Vendor overview
  • Exhibit 52: AstraZeneca - Business segments
  • Exhibit 53: AstraZeneca - Organizational developments
  • Exhibit 54: AstraZeneca - Geographic focus
  • Exhibit 55: AstraZeneca - Key offerings
  • Exhibit 56: Boehringer Ingelheim - Vendor overview
  • Exhibit 57: Boehringer Ingelheim - Business segments
  • Exhibit 58: Boehringer Ingelheim - Organizational developments
  • Exhibit 59: Boehringer Ingelheim - Geographic focus
  • Exhibit 60: Boehringer Ingelheim - Segment focus
  • Exhibit 61: Boehringer Ingelheim - Key offerings
  • Exhibit 62: GlaxoSmithKline - Vendor overview
  • Exhibit 63: GlaxoSmithKline - Business segments
  • Exhibit 64: GlaxoSmithKline - Organizational developments
  • Exhibit 65: GlaxoSmithKline - Geographic focus
  • Exhibit 66: GlaxoSmithKline - Segment focus
  • Exhibit 67: GlaxoSmithKline - Key offerings
  • Exhibit 68: Novartis - Vendor overview
  • Exhibit 69: Novartis - Business segments
  • Exhibit 70: Novartis - Organizational developments
  • Exhibit 71: Novartis - Geographic focus
  • Exhibit 72: Novartis - Segment focus
  • Exhibit 73: Novartis - Key offerings
  • Exhibit 74: Teva Pharmaceutical - Vendor overview
  • Exhibit 75: Teva Pharmaceutical - Business segments
  • Exhibit 76: Teva Pharmaceutical - Organizational developments
  • Exhibit 77: Teva Pharmaceutical - Geographic focus
  • Exhibit 78: Teva Pharmaceutical - Segment focus
  • Exhibit 79: Teva Pharmaceutical - Key offerings
  • Exhibit 80: Validation techniques employed for market sizing
  • Exhibit 81: List of abbreviations
Back to Top